BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Other News

Amgen autoimmune news

Amgen said the U.S. Patent and Trademark Office issued a patent covering the fusion protein that constitutes autoimmune drug Enbrel etanercept. The patent, which expires in 2028, describes the non-soluble proteins and soluble or insoluble fragments thereof that bind tumor necrosis factor (TNF). Amgen markets Enbrel in the U.S. and Canada with ...

Read the full 265 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >